L'intérêt à découvert pour Ginkgo Bioworks Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Ginkgo Bioworks Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Ginkgo Bioworks Holdings (NYSE:DNA) Stock, Rapport sur les intérêts à découvert

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

CIBC analyst Krista Friesen maintains Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) with a Outperformer and raises the price target from C$134 to C$139.

News

Price Target

Analyst Ratings

TSX:STN

CIBC Maintains Outperformer on Stantec, Raises Price Target to C$139

CIBC analyst Paul Holden maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Outperformer and raises the price target from C$154 to C$156.

TSX:BMO

CIBC Maintains Outperformer on Bank of Montreal, Raises Price Target to C$156

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 1.65% on an annualized basis producing an average annual return of 12.56%. Currently, AECOM has a market capitalization of $13.06 billion. 
Buying $1000 In ACM: If an investor had bought $1000 of ACM stock 10 years ago, it would be worth $3,254.71 today based on a price of $98.39 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740611952_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $115 to $111.

MMSI

Barrington Research Maintains Outperform on Merit Medical Systems, Lowers Price Target to $111

Telsey Advisory Group analyst Cristina Fernandez maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Outperform and maintains $11 price target.

ARHS

Telsey Advisory Group Maintains Outperform on Arhaus, Maintains $11 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 10 years by 5.73% on an annualized basis producing an average annual return of 16.64%. Currently, Domino's Pizza has a market capitalization of $16.43 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 10 years ago, it would be worth $4,587.42 today based on a price of $479.11 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740611037_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Domino's Pizza 10 Years Ago Would Be Worth This Much Today

Macquarie analyst Chad Beynon maintains AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) with a Neutral and maintains $4 price target.

Macquarie Maintains Neutral on AMC Enter Hldgs, Maintains $4 Price Target

Tigress Financial analyst Ivan Feinseth maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Strong Buy and raises the price target from $265 to $285.

GRMN

Tigress Financial Maintains Strong Buy on Garmin, Raises Price Target to $285

Payfare Inc. ("Payfare" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAY#TSX">PAY</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/PYFRF#OTCQX">PYFRF</a>) announced today that the Supreme Court of British Columbia (the "Court") has issued a final order approving the previously announced plan of arrangement (the "Arrangement") pursuant to which 1517452 B.C. Ltd. (the "Purchaser"), an affiliate of Fiserv, Inc. ("Fiserv") will acquire all of the issued and outstanding Class A Common shares of Payfare.

PYFRF

TSX:PAY

Fiserv Affiliate 1517452 B.C. Ltd. To Acquire Payfare Shares Following British Columbia Supreme Court Approval Of Arrangement

Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/02/g43990904/kratos-rafael-establish-prometheus-energetics-joint-venture-a-u-s-based-merchant-supplier-of-solid">figures from the report. </a>
The Details: Kratos Defense &amp; Security reported quarterly earnings of 11 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $1.13 billion which missed the analyst consensus estimate of $1.14 billion.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43949800/tesla-competes-against-chinese-rivals-with-one-hand-tied-behind-its-back-analyst"> Tesla Competes Against Chinese Rivals &#8216;With One Hand Tied Behind Its Back&#8217;: Analyst</a>
Kratos also announced an approximate 50/50 partnership with RAFAEL Advanced Defense Systems Ltd. for the establishment of a U.S.-based merchant supplier of solid rocket motors and other energetics. The new joint venture, named Prometheus Energetics, is set to be headquartered on an approximate 500-acre site near the U.S. Navy and Army facility in Crane, Indiana.
&#8220;Kratos&#8217; full year 2024 and fourth quarter demonstrated once again that we can significantly organically grow the business, and make sizable internally funded investments, positioning the Company for accelerating future growth, while also generating significant, positive operating cash flow,&#8221; said Eric DeMarco, Kratos&#8217; president and CEO. 
&#8220;We have recently received several large new program and contract awards, including in the hypersonic, target drone, jet engine, rocket and satellite system areas, enabling us to increase our expected revenue growth rate for 2026 to a range of 13 percent to 15 percent above our current 2025 financial forecast that we provided today, which includes 10 percent growth over 2024,&#8221; DeMarco added.  
KTOS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Kratos Defense &amp; Security Solutions shares are down 8.37% after-hours at $22.87 Wednesday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;&nbsp;</a></li>
</ul>
Image courtesy of Kratos Defense &amp; Security Solutions, Inc.&nbsp;

Earnings

After-Hours Center

Movers

Tech

KTOS

Kratos Defense & Security Shares Fall After Q4 Revenues Miss Estimates

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and maintains $7 price target.

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

The Company receives Nasdaq notification letters
Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) ("SMCI" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage and 5G/Edge, today announced that on February 25, 2025 it received a notification letter from Nasdaq indicating that it now complies with Nasdaq Listing Rule 5250(c)(1) which requires timely filing of reports with the U.S. Securities and Exchange Commission and the matter is now closed.
Prior to its filing on February 25, 2025, the Company had received a notification letter from Nasdaq on February 21, 2025, stating that the Company was not in compliance with Nasdaq listing rule 5250(c)(1) as a result of the Company's delay in filing its Q2 FY2025 Form 10-Q and its continued delay in filing its FY2024 Form 10-K and Q1 FY2025 Form 10-Q. As previously announced, on February 25, 2025, the Company has filed each of such periodic reports such that it is now current with respect to its Securities Exchange Act reporting obligations.

SMCI

Super Micro Computer Receives Notification Letter From Nasdaq Indicating That It Now Complies With Nasdaq Listing Standards

Company expects to start trading on OTCQX under the symbol "LICYF" on February 27, 2025 following suspension of trading on the NYSE
OTCQX to provide Li-Cycle efficient access to U.S. capital markets while reducing costs and streamlining market requirements
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fli-cycle.com%2F&amp;esheet=54215936&amp;newsitemid=20250226390364&amp;lan=en-US&amp;anchor=Li-Cycle+Holdings+Corp.&amp;index=1&amp;md5=afcfe13ab46dc3cfe1523b5705041aa5">Li-Cycle Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) ("Li-Cycle" or the "Company"), a leading global lithium-ion battery resource recovery company, today announced that its common shares have been approved to trade on the OTCQX&#xAE; Best Market, and that it expects its common shares to commence trading on OTCQX under the symbol "LICYF" on February 27, 2025, when it expects to be eligible for quotation.

LICY

Li-Cycle Announces That Its Common Shares Have Been Approved To Trade On The OTCQX Best Market, And That It Expects Its Common Shares To Commence Trading On OTCQX Under The Symbol "LICYF" On February 27, 2025

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 79.3% on an annualized basis producing an average annual return of 93.94%. Currently, Antero Resources has a market capitalization of $11.53 billion. 
Buying $1000 In AR: If an investor had bought $1000 of AR stock 5 years ago, it would be worth $25,197.28 today based on a price of $37.04 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740609982_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Tandy Leather Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLF#NASDAQ">TLF</a>) reported quarterly earnings of $0.04 per share. This is a 82.61 percent decrease over earnings of $0.23 per share from the same period last year. The company reported $20.50 million in sales this quarter. This is a 1.66 percent decrease over sales of $20.84 million the same period last year.

Tandy Leather Factory Q4 EPS $0.04 Down From $0.23 YoY, Sales $20.50M Down From $20.84M YoY

Energy Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) sees FY2025 sales of $152.000 million-$164.000 million vs $159.14 million analyst estimate.

Guidance

ERII

Energy Recovery Sees FY2025 Sales $152.000M-$164.000M vs $159.14M Est

Insurance company Root Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) reported fourth-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>
Here are the key highlights.
 What Happened: Root reported fourth-quarter revenue of $326.7 million, beating a Street consensus estimate of $291.0 million according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022625&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company <a href="https://ir.joinroot.com/news-releases/news-release-details/root-inc-announces-2024-fourth-quarter-and-full-year-results">reported </a>fourth-quarter earnings per share of $1.62, beating a Street consensus estimate of a loss of 44 cents per share.
The company reported policies in force grew 21% year-over-year in the quarter. Gross premiums written were up 18% year-over-year in the quarter.
Gross accident period losses were down in the quarter.
Root reported positive net income for the second consecutive quarter and had a positive net income of $31 million for the full fiscal year, an improvement of $178 million from the previous fiscal year.
The company called 2024 "a landmark year" and said it was made possible by hard decisions made in 2022 and 2023.
"Ten years ago, we believed that modern quantitative methods would allow us to grow at better loss ratios than the industry. Today our loss ratio is among the best in the industry," the company said.
Root said it continues to invest in infrastructure and growth, which should translate to "strong calendar period results" as the company gains scale.
"We believe our patience and foundation in data science will continue to bear fruit that will ultimately accrue to long-term stakeholders."
ROOT Price Action: Root stock is up 17.52% to $116 in after-hours trading Wednesday versus a 52-week trading range of $20.22 to $141.23.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/quote/ROOT/analyst-ratings">Analyst Ratings For ROOT </a></li>
</ul>
Photo: MacroEcon via Shutterstock

Insurance

ROOT

Why Shares Of Insurance Company Root Are Soaring Wednesday

MESO

Mesoblast H1 2025 EPADS $(4.20) Down From $(3.72) YoY; Revenue $3.156M Down From $3.388M YoY

Cantor Fitzgerald analyst Charles Duncan downgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Overweight to Neutral and raises the price target from $140 to $150.

Downgrades

JAZZ

Cantor Fitzgerald Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $150

Press Releases

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Alto Ingredients

Ashland

ASP Isotopes

Aspen Aerogels

Avient

Bon Natural Life Limited - Ordinary Shares

Bon Natural Life

Ecovyst

Flexible Solutions International Inc. Common Stock (CDA)

Flexible Solutions Intl

Flotek Industries

H.B. Fuller

Innospec

Quaker Houghton

Minerals Technologies

Ingevity

Northern Technologies International Corporation - Common Stock

Northern Technologies

Perimeter Solutions

Rayonier Advanced Materials Inc. Common Stock

Rayonier Adv Materials

Stepan

Sensient Technologies Corporation Common Stock

Sensient Technologies

Valhi

TD Cowen

BTIG

Goldman Sachs

Morgan Stanley

Genentech

WIIM

Ginkgo Bioworks Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY25 revenue guidance below estimates.

Comments

Ginkgo Bioworks Holdings

Intérêt court

Ginkgo Bioworks Holdings (NYSE:DNA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL